NEW YORK, November 19, 2019 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory
and autoimmune diseases, today announced the appointment of Barclay "Buck" A. Phillips, an established
life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019.
With this addition, Immunic's Board will total seven members.
"Buck's decades of relevant experience in the biotechnology sector, both as a Chief Financial Officer and
investor, will add a unique perspective to our Board," stated Duane Nash, M.D., J.D., M.B.A., Chairman of
the Board of Directors of Immunic. "We look forward to leveraging his significant expertise in the areas of
financing strategy, capital markets, business development, and others, which he has garnered during his
successful career as an executive and board member for multiple, Nasdaq-listed life science companies.
Buck's addition to our team reflects our desire to build the Board during a time of continued clinical
progress and we look forward to his contributions."
Until recently, Mr. Phillips was Chief Financial Officer and Senior Vice President of Corporate Development
at G1 Therapeutics, Inc., where, among other achievements, he was instrumental in raising over USD 300
million in multiple equity financings. Before that, he served as Senior Vice President, Chief Financial Officer
and Treasurer of vaccine company, Novavax, Inc., where he helped to raise more than USD 850 million in
various financings to support the company's late-stage clinical programs. Prior, Mr. Phillips was Senior
Vice President and Chief Financial Officer of Micromet, Inc., which, during his tenure, was acquired by
Amgen Inc. for approximately USD 1.2 billion. Mr. Phillips's exposure to venture capital came earlier, while
serving as a Managing Director at Vector Fund Management, focused on investments in late-stage life
sciences companies, and during his time as Biotechnology Analyst and Director of Venture Investments at
Invesco, where he held primary coverage responsibility for the universe of publicly traded biotechnology
companies, while managing the firm's private equity investing, with a focus on life sciences.
Mr. Phillips has served on the boards of over a dozen public and private life sciences companies. He earned
a Bachelor of Arts in economics from the University of Colorado at Boulder.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of
selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases,
including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The
company is developing three small molecule products: IMU-838 is a selective immune modulator that
inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935
is an inverse agonist of RORyt; and IMU-856 targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting
multiple sclerosis and ulcerative colitis, with an additional phase 2 trial planned in Crohn's disease. An
investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is
ongoing at the Mayo Clinic. For further information, please visit: www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, included in this press release regarding strategy,
future operations, future financial position, future revenue, projected expenses, prospects, plans and
objectives of management are forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to Immunic's clinical and preclinical pipeline activities and the structure
and composition of its board. Immunic may not actually achieve the plans, carry out the intentions or
meet the expectations or projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Such statements are based on management's
current expectations and involve risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, risks and uncertainties associated with the ability to project future cash utilization and
reserves needed for contingent future liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity
provided by Immunic's intellectual property, risks related to the drug development and the regulatory
approval process and the impact of competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be found in the section captioned "Item
1A. Risk Factors," in the company's Current Report on Form 8-K filed on July 17, 2019, and in the
company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or ir.immunic-therapeutics.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect events or circumstances that exist after
the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or
not taken based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com